Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and End-use Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Biotechnology & Pharmaceutical Services Outsourcing Market, By Service
7.1. Biotechnology & Pharmaceutical Services Outsourcing Market, by Service, 2021-2030
7.1.1. Consulting
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Auditing and Assessment
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. Regulatory Affairs
7.1.3.1. Market Revenue and Forecast (2017-2030)
7.1.4. Product Maintenance
7.1.4.1. Market Revenue and Forecast (2017-2030)
7.1.5. Product Design & Development
7.1.5.1. Market Revenue and Forecast (2017-2030)
7.1.6. Product Testing & Validation
7.1.6.1. Market Revenue and Forecast (2017-2030)
7.1.7. Training & Education
7.1.7.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Biotechnology & Pharmaceutical Services Outsourcing Market, By End-use
8.1. Biotechnology & Pharmaceutical Services Outsourcing Market, by End-use, 2021-2030
8.1.1. Pharma
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Biotech
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Biotechnology & Pharmaceutical Services Outsourcing Market, Regional Estimates and Trend Forecast
9.1. North America
9.1.1. Market Revenue and Forecast, by Service (2017-2030)
9.1.2. Market Revenue and Forecast, by End-use (2017-2030)
9.1.3. U.S.
9.1.3.1. Market Revenue and Forecast, by Service (2017-2030)
9.1.3.2. Market Revenue and Forecast, by End-use (2017-2030)
9.1.4. Rest of North America
9.1.4.1. Market Revenue and Forecast, by Service (2017-2030)
9.1.4.2. Market Revenue and Forecast, by End-use (2017-2030)
9.2. Europe
9.2.1. Market Revenue and Forecast, by Service (2017-2030)
9.2.2. Market Revenue and Forecast, by End-use (2017-2030)
9.2.3. UK
9.2.3.1. Market Revenue and Forecast, by Service (2017-2030)
9.2.3.2. Market Revenue and Forecast, by End-use (2017-2030)
9.2.4. Germany
9.2.4.1. Market Revenue and Forecast, by Service (2017-2030)
9.2.4.2. Market Revenue and Forecast, by End-use (2017-2030)
9.2.5. France
9.2.5.1. Market Revenue and Forecast, by Service (2017-2030)
9.2.5.2. Market Revenue and Forecast, by End-use (2017-2030)
9.2.6. Rest of Europe
9.2.6.1. Market Revenue and Forecast, by Service (2017-2030)
9.2.6.2. Market Revenue and Forecast, by End-use (2017-2030)
9.3. APAC
9.3.1. Market Revenue and Forecast, by Service (2017-2030)
9.3.2. Market Revenue and Forecast, by End-use (2017-2030)
9.3.3. India
9.3.3.1. Market Revenue and Forecast, by Service (2017-2030)
9.3.3.2. Market Revenue and Forecast, by End-use (2017-2030)
9.3.4. China
9.3.4.1. Market Revenue and Forecast, by Service (2017-2030)
9.3.4.2. Market Revenue and Forecast, by End-use (2017-2030)
9.3.5. Japan
9.3.5.1. Market Revenue and Forecast, by Service (2017-2030)
9.3.5.2. Market Revenue and Forecast, by End-use (2017-2030)
9.3.6. Rest of APAC
9.3.6.1. Market Revenue and Forecast, by Service (2017-2030)
9.3.6.2. Market Revenue and Forecast, by End-use (2017-2030)
9.4. MEA
9.4.1. Market Revenue and Forecast, by Service (2017-2030)
9.4.2. Market Revenue and Forecast, by End-use (2017-2030)
9.4.3. GCC
9.4.3.1. Market Revenue and Forecast, by Service (2017-2030)
9.4.3.2. Market Revenue and Forecast, by End-use (2017-2030)
9.4.4. North Africa
9.4.4.1. Market Revenue and Forecast, by Service (2017-2030)
9.4.4.2. Market Revenue and Forecast, by End-use (2017-2030)
9.4.5. South Africa
9.4.5.1. Market Revenue and Forecast, by Service (2017-2030)
9.4.5.2. Market Revenue and Forecast, by End-use (2017-2030)
9.4.6. Rest of MEA
9.4.6.1. Market Revenue and Forecast, by Service (2017-2030)
9.4.6.2. Market Revenue and Forecast, by End-use (2017-2030)
9.5. Latin America
9.5.1. Market Revenue and Forecast, by Service (2017-2030)
9.5.2. Market Revenue and Forecast, by End-use (2017-2030)
9.5.3. Brazil
9.5.3.1. Market Revenue and Forecast, by Service (2017-2030)
9.5.3.2. Market Revenue and Forecast, by End-use (2017-2030)
9.5.4. Rest of LATAM
9.5.4.1. Market Revenue and Forecast, by Service (2017-2030)
9.5.4.2. Market Revenue and Forecast, by End-use (2017-2030)
Chapter 10. Company Profiles
10.1. The Quantic Group
10.1.1. Company Overview
10.1.2. Service Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. IQVIA
10.2.1. Company Overview
10.2.2. Service Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. Parexel International Corporation
10.3.1. Company Overview
10.3.2. Service Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. Lachman Consultant Services, Inc.
10.4.1. Company Overview
10.4.2. Service Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. GMP Pharmaceuticals Pty Ltd.
10.5.1. Company Overview
10.5.2. Service Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. Concept Heidelberg GmbH
10.6.1. Company Overview
10.6.2. Service Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. Covance Inc.
10.7.1. Company Overview
10.7.2. Service Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. Richard Wolf GmbH
10.8.1. Company Overview
10.8.2. Service Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
10.9. Charles River Laboratories
10.9.1. Company Overview
10.9.2. Service Offerings
10.9.3. Financial Performance
10.9.4. Recent Initiatives
10.10. PRA Health Sciences
10.10.1. Company Overview
10.10.2. Service Offerings
10.10.3. Financial Performance
10.10.4. Recent Initiatives
Chapter 11. Research Methodology
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
Chapter 12. Appendix
12.1. About Us
12.2. Glossary of Terms